title: An HBV-HIV co-infected patient treated with tenofovir-based therapy who achieved HBs antigen/antibody seroconversion.
abstract: The present report describes a case of a patient with hepatitis B virus (HBV)-human immunodeficiency virus (HIV) co-infection who was treated with tenofovir disoproxil (TDF)-based highly active antiretroviral therapy (HAART) and who achieved HBs antigen (Ag)/antibody (Ab) seroconversion. An 18-year-old Japanese man with HIV and HBV co-infection presented to our hospital. His CD4 count was decreased, and TDF-based HARRT was started. At 30 months after initiation of therapy, HBsAg was not detected. At 36 months after initiation of therapy, HBsAb was detected. We conclude that TDF-based therapy is useful for the management of patients with HBV and HIV co-infection.
authors.affiliation: Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Japan.
authors.forename: Takao
authors.initials: T
authors.lastname: Watanabe
authors.forename: Yoshio
authors.initials: Y
authors.lastname: Tokumoto
authors.forename: Masashi
authors.initials: M
authors.lastname: Hirooka
authors.forename: Yohei
authors.initials: Y
authors.lastname: Koizumi
authors.forename: Fujimasa
authors.initials: F
authors.lastname: Tada
authors.forename: Hironori
authors.initials: H
authors.lastname: Ochi
authors.forename: Masanori
authors.initials: M
authors.lastname: Abe
authors.forename: Teru
authors.initials: T
authors.lastname: Kumagi
authors.forename: Yoshio
authors.initials: Y
authors.lastname: Ikeda
authors.forename: Bunzo
authors.initials: B
authors.lastname: Matsuura
authors.forename: Kiyonori
authors.initials: K
authors.lastname: Takada
authors.forename: Yoichi
authors.initials: Y
authors.lastname: Hiasa
mesh_terms: D000225:Adenine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000293:Adolescent; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active; D060085:Coinfection / Q000097:blood / Q000188:drug therapy; D015658:HIV Infections / Q000097:blood / Q000150:complications* / Q000188:drug therapy*; D006509:Hepatitis B / Q000097:blood / Q000150:complications* / Q000188:drug therapy*; D006510:Hepatitis B Antibodies / Q000097:blood; D006514:Hepatitis B Surface Antigens / Q000097:blood; D006801:Humans; D008297:Male; D063065:Organophosphonates / Q000627:therapeutic use*; D000068698:Tenofovir
chemical_list: D019380:Anti-HIV Agents; D006510:Hepatitis B Antibodies; D006514:Hepatitis B Surface Antigens; D063065:Organophosphonates; D000068698:Tenofovir; D000225:Adenine